Lee CH, et al. - Patients treated with second-generation drug-eluting stents (DES) for coronary artery disease were assessed in this study in order to determine the impact of triple antiplatelet therapy on clinical outcomes in these subjects. Following implantation of second-generation DES, improved clinical outcomes were seen among those who received triple antiplatelet therapy with cilostazol, which mainly caused a reduction in target vessel revascularization (TVR).